Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05285553 · ClinicalTrials.gov registry record · NA
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
A NA study of Myopia, sponsored by CooperVision.
- Recruiting
- Registry status
- NA
- Development phase
- 900
- Enrollment target
- 20
- Study locations
NCT05285553: Recruiting NA study of Myopia, sponsored by CooperVision.
NCT05285553 is a NA study of Myopia that is actively recruiting participants, run by CooperVision. The registered enrollment target is 900 participants, above the 258-participant average among 90 other Myopia trials with a reported enrollment target (249% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05285553, a NA study of Myopia, is actively recruiting participants, sponsored by CooperVision.
- RECRUITING
- Registry status
- NA
- Development phase
- 900 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Primary Outcome
Mean difference in cycloplegic SERE change from baseline; measured with cycloplegic auto-refraction in Diopters
Conditions Studied
Interventions
- DEVICE MiSight 1 Day
- DEVICE Proclear 1 day
Study Locations (20)
Illinois
- SoLo Eye Care & Eyewear Gallery - Chicago
- Illinois College of Optometry - Chicago
- Chicago College of Optometry - Downers Grove
- Carillon Vision Care - Glenview
- Brain Vision Institute - Schaumburg
California
- Marshall B. Ketchum University Southern California College of Optometry - Fullerton
- Vision Solutions Optometry Inc - La Mesa
- Paje Optometric - Santa Ana
Florida
- Coan Eye Care and Optical Boutique - Ocoee
- West Broward Eyecare Associates - Tamarac
- Bright Eyes Family Vision Care - Tampa
Ohio
- Athens Eye Care - Athens
- Ohio State University - Columbus
- ProCare Vision Center, Inc. - Granville
Alabama
- University of Alabama School of Optometry - Birmingham
Indiana
- Clinical Optics Research Lab at IU School of Optometry - Bloomington
Kansas
- Kannarr Eye Care - Pittsburg
Massachusetts
- New England College of Optometry - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2022-06-25 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05285553 shows while recruiting
NCT05285553 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 258-participant average among 90 other Myopia trials with a reported enrollment target (249% higher).
The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which MiSight 1 Day is the first listed.
NCT05285553 names 20 study sites across 10 states, led by Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05285553 about?
NCT05285553 is a clinical study titled "MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms". The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
What is the current status of trial NCT05285553?
This trial is currently recruiting. It is a NA study. The enrollment target is 900 participants. The study started on 2022-06-25. Estimated completion is 2027-06-30.
What conditions does trial NCT05285553 study?
This clinical trial studies the following conditions: Myopia.
What interventions are being tested in trial NCT05285553?
The interventions under investigation include: MiSight 1 Day (DEVICE), Proclear 1 day (DEVICE).
Who is sponsoring clinical trial NCT05285553?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05285553 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05285553's enrollment target sits among peer trials
900 4th of 90 higher than 87 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI